{"symbol": "PSTI", "companyName": "Pluristem Therapeutics Inc", "exchange": "NASDAQ", "industry": "Biological Product (except Diagnostic) Manufacturing ", "website": "www.pluristem.com", "description": "Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off- the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a", "CEO": "Yaky Yanay", "securityName": "Pluristem Therapeutics Inc", "issueType": "cs", "sector": "Manufacturing", "primarySicCode": 2836, "employees": 180, "tags": ["Health Technology", "Biotechnology", "Manufacturing", "Biological Product (except Diagnostic) Manufacturing "], "address": "Matam Advanced Technology Park", "address2": null, "state": "Haifa", "city": "Building No 5", "zip": "3508409", "country": "Israel", "phone": "972747107171"}